Abstract
Modeling treatment effect could identify a subgroup of individuals who experience greater benefit from disease modifying therapy, allowing for predictive enrichment to increase the power of future clinical trials. We use deep learning to estimate the conditional average treatment effect for individuals taking disease modifying therapies for multiple sclerosis, using their baseline clinical and imaging characteristics. Data were obtained as part of three placebo-controlled randomized clinical trials: ORATORIO, OLYMPUS and ARPEGGIO, investigating the efficacy of ocrelizumab, rituximab and laquinimod, respectively. A shuffled mix of participants having received ocrelizumab or rituximab, anti-CD20-antibodies, was separated into a training (70%) and testing (30%) dataset, but we also performed nested cross-validation to improve the generalization error estimate. Data from ARPEGGIO served as additional external validation. An ensemble of multitask multilayer perceptrons was trained to predict the rate of disability progression on both active treatment and placebo to estimate the conditional average treatment effect. The model was able to separate responders and non-responders across a range of predicted effect sizes. Notably, the average treatment effect for the anti-CD20-antibody test set during nested cross-validation was significantly greater when selecting the model’s prediction for the top 50% (HR 0.625, p=0.008) or the top 25% (HR 0.521, p=0.013) most responsive individuals, compared to HR 0.835 (p=0.154) for the entire group. The model trained on the anti-CD20-antibody dataset could also identify responders to laquinimod, finding a significant treatment effect in the top 30% of individuals (HR 0.352, p=0.043). We observed enrichment across a broad range of baseline features in the responder subgroups: younger, more men, shorter disease duration, higher disability scores, and more lesional activity. By simulating a 1-year study where only the 50% predicted to be most responsive are randomized, we could achieve 80% power to detect a significant difference with 6 times less participants than a clinical trial without enrichment. Subgroups of individuals with primary progressive multiple sclerosis who respond favourably to disease modifying therapies can therefore be identified based on their baseline characteristics, even when no significant treatment effect can be found at the whole-group level. The approach allows for predictive enrichment of future clinical trials, as well as personalized treatment selection in the clinic.
Competing Interest Statement
Arnold, DL, reports consulting fees from Albert Charitable Trust, Alexion Pharma, Biogen, Celgene, Frequency Therapeutics, Genentech, Med-Ex Learning, Merck, Novartis, Population Council, Receptos, Roche, and Sanofi-Aventis, grants from Biogen, Immunotec and Novartis, and an equity interest in NeuroRx. Sormani, MP, has received personal compensation for consulting services and for speaking activities from Merck, Teva, Novartis, Roche, Sanofi Genzyme, Medday, GeNeuro, and Biogen. Precup, D, works part-time for DeepMind. The remaining authors report no competing interests.
Funding Statement
This investigation was supported (in part) by an award from the International Progressive Multiple Sclerosis Alliance (award reference number PA-1412-02420), by an endMS Personnel Award from the Multiple Sclerosis Society of Canada (Falet, JR), and by a Canada Graduate Scholarship-Masters Award from the Canadian Institutes of Health Research (Falet, JR). Falet, JR is also being supported through the Fonds de recherche Santé / Ministère de la Santé et des Services sociaux training program for specialty medicine residents with an interest in pursuing a research career, Phase 1.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the Montreal Neurological Institute gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data used in this work are controlled by pharmaceutical companies and therefore are not publicly available. Access requests should be forwarded to data controllers via the corresponding author.
Abbreviations
- CATE
- Conditional average treatment effect
- CDP
- Confirmed Disability Progression
- CPH
- Cox Proportional Hazards
- CV
- Cross-validation
- EDSS
- Expanded Disability Status Scale
- Gad
- Gadolinium-enhancing lesion
- ITE
- Individual treatment effect
- MLP
- Multi-layer perceptron
- PPMS
- Primary progressive multiple sclerosis
- RRMS
- Relapsing-remitting multiple sclerosis
